TruSight Oncology 500 (TSO500)

An Efficient, Reliable Solution for Non-Invasive Tumor Characterization

Minimal input, extensive results

Obtain full exon coverage of 522 out of 523 genes using as little as 3 mL of plasma, 20-30 ng of cfDNA, or 10 mL of whole blood. TSO500 ctDNA can detect biomarkers without the need of a matched normal sample.

Simple, cost-effective workflow

Detect multiple biomarkers with a single assay to save time, money, and samples. The distributable kit enables global implementation.

Confident variant detection

Obtain a high-resolution view of variants enabled by TSO500 ctDNA’s hybrid-capture chemistry and unique molecular indices (UMIs).

Measurement of key immuno-oncology biomarkers

Gain insight into TMB score and MSI score in addition to variant calls. TruSight Oncology 500 ctDNA can reproducibly assess TMB.

Expansive services enabled by our global network

Our centralized, scientific operational oversight combined with our global laboratory footprint enable comprehensive, large-scale trial support. We enable clinical development support irrespective of geography.

Flexible customization to satisfy specific needs

We work with you to understand your specific needs, and our team provides cost-effective recommendations from custom assay development to specialized bioinformatics support.

Deep Sequencing Enabled by IQVIA Laboratories Subject Matter Expertise

Feel confident in your results with the trusted Illumina® software pipeline. Our software teams validate the most up-to-date software to ensure you are receiving optimal results. IQVIA Laboratories can develop custom reporting and filtering to meet your specific research needs. IQVIA Laboratories was one of the earliest adopters of DRAGEN™. Our technical support teams help you understand your deep sequencing data with our superior bioinformatics knowledge.

Validated up to CAP/CLIA standards

IQVIA Laboratories offers this TSO500 assay at multiple regulatory levels, from Research Use Only (RUO) to Good Clinical Practices (GCP) to CAP/CLIA, depending on the intended use of the assay by our client. Please reach out to our IQVIA Laboratories Genomics Business Development team to discuss your intended use so we can better guide which regulatory level is most appropriate for your clinical or research program(s).